- Report
- May 2025
- 187 Pages
Global
From €3211EUR$3,545USD£2,768GBP
€3568EUR$3,939USD£3,076GBP
- Report
- August 2024
- 121 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Report
- May 2025
- 193 Pages
Global
From €3211EUR$3,545USD£2,768GBP
€3568EUR$3,939USD£3,076GBP
- Report
- July 2025
Global
From €4439EUR$4,900USD£3,826GBP
From €4439EUR$4,900USD£3,826GBP
- Report
- July 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- April 2025
- 175 Pages
Global
From €4067EUR$4,490USD£3,506GBP
- Report
- July 2025
- 240 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- July 2025
- 377 Pages
Global
From €5299EUR$5,850USD£4,568GBP
- Report
- April 2025
- 185 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Report
- March 2025
- 180 Pages
Global
From €3465EUR$3,825USD£2,987GBP
€4077EUR$4,500USD£3,514GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1812EUR$2,000USD£1,562GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1812EUR$2,000USD£1,562GBP
- Drug Pipelines
- April 2025
- 280 Pages
Global
From €2718EUR$3,000USD£2,343GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1359EUR$1,500USD£1,171GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1132EUR$1,250USD£976GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1132EUR$1,250USD£976GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1132EUR$1,250USD£976GBP
- Report
- October 2024
- 318 Pages
Global
From €7202EUR$7,950USD£6,208GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2527EUR$2,789USD£2,178GBP

Dyskinesia is a neurological disorder characterized by involuntary, repetitive movements. It is most commonly associated with the use of certain central nervous system drugs, such as antipsychotics and levodopa. Dyskinesia can cause a range of physical symptoms, including jerky movements, tremors, and difficulty with coordination. It can also lead to psychological symptoms, such as anxiety and depression.
The dyskinesia market is composed of a range of pharmaceutical companies that produce drugs to treat the disorder. These companies develop and market medications that can reduce the severity of symptoms and improve quality of life. Many of these drugs are approved by the FDA and are available in both generic and brand-name forms.
Some of the companies in the dyskinesia market include AbbVie, Allergan, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more